ERBB2 and breast carcinoma: Also, a drug screening targeting receptor tyrosine-protein kinase erbB2 (HER2) signaling, in a biobank representing breast cancer heterogeneity with over 100 PDOs, demonstrated that sensitivity to drug treatment correlates with HER2 status (Sachs et al., 2018).